Innovating Works

DIGI-B-CUBE

Financiado
Digital Enterprise Innovations for Bioimaging, Biosensing and Biobanking Industries DIGI-B-CUBE project aims to unlock the cross-sectoral collaborative potential of SMEs by combining Artificial Intelligence (AI), Cognitive Computing Digital Technologies (CCDT) with the Bioimaging-Biosensing-Biobanking (B-CUBE) in... DIGI-B-CUBE project aims to unlock the cross-sectoral collaborative potential of SMEs by combining Artificial Intelligence (AI), Cognitive Computing Digital Technologies (CCDT) with the Bioimaging-Biosensing-Biobanking (B-CUBE) industries to deliver market sensitive disruptive technologies and generating innovative solutions that enhance patient-centred diagnostic work-flows, delivered through the improved algorithms for Medical Diagnostics’ efficiency and accuracy. DIGI-B-CUBE will study the characteristics in market dynamics & specificities for innovations created by merging AI, CCDT & B-CUBE industries. By providing a framework for a more structured cross-sectoral and cross-border collaboration, that manages all the complex work-flows within the process, DIGI-B-CUBE instantiates the mechanisms to ensure the long-term sustainability of the action through collaborations of the participating clusters with hospitals, academia, industry, investors, business angels, managing authorities of the national innovation agencies and the European Commission support measures (such as EIT, ESIF). The main objective of this project is to provide key digital solutions for the reconfiguration of the Medical Diagnostics value chain towards a Health Economy 4.0 with a special focus on Biobanking, Bioimaging and Biosensing industries. Activities financed by the ESIF in the participating regions as part of the Smart Specialisation Strategies will be bundled in cooperation with the responsible managing authorities in addition to the innovation voucher scheme for SMEs. By integrating innovations in IT into Bioimaging, Biosensing and Biobanking industries, this project will accelerate the goal of personalised medicine that can eventually offer patients with fast and efficient diagnosis-treatment-healthcare system. ver más
30/04/2022
5M€
Duración del proyecto: 35 meses Fecha Inicio: 2019-05-01
Fecha Fin: 2022-04-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2022-04-30
H2020 No se conoce la línea exacta de financiación, pero conocemos el organismo encargado de la revisión del proyecto.
Presupuesto El presupuesto total del proyecto asciende a 5M€
Líder del proyecto
OSLO CANCER CLUSTER SA No se ha especificado una descripción o un objeto social para esta compañía.